JMA, MHLW Say Possible Opdivo Re-Pricing Is Emergency Step, Won’t Make It Slippery Slope to Annual Revisions

JMA President Yoshitake Yokokura The leader of Japan’s biggest doctors lobby and a key health ministry official say an envisioned “special measure” for the reimbursement price of Opdivo (nivolumab) will merely be a one-time emergency step for defending the country’s...read more